NYHQ is seeking individuals to take part in a Phase 2 clinical research study of adults with active Crohn’s disease, a chronic gastrointestinal disease with no cure.
The OPERA study will evaluate the safety and tolerability of an investigational drug and its effect on the symptoms of Crohn’s disease, particularly those related to inflammation of the gastrointestinal tract. Moshe Rubin, M.D., director, Division of Gastroenterology, is the principal investigator at NYHQ.
Individuals may be eligible to enroll in the study if they are:
Interested individuals can contact Ajini Cherian, research coordinator, Theresa and Eugene M. Lang Center for Research and Education, at 718-670-1827 or email@example.com.
Take this survey to see if you are eligible for enrollment: www.pacerresearch.com/crohns
This survey is completely anonymous. This survey does not screen for every criteria, but it is the first step to determine eligibility for this study. If eligible, an individual can consent to taking part in the study and will receive follow up information on how to proceed or, an individual can opt-out of participating and record of the survey will be deleted.